For children and patients undergoing therapies, treatment is still associated with fear, anxiety, and discomfort. 

Home to nearly 60% of the world’s population, Asia-Pacific is emerging as one of the world’s most dynamic healthcare markets. Yet it also faces some of healthcare’s greatest challenges.

According to the World Economic Forum (WEF) the region is simultaneously navigating rising healthcare costs, projected to exceed 10 to 12% annually, alongside ageing populations, workforce shortages, and a growing burden of chronic diseases, placing unprecedented pressure on health systems to deliver better outcomes with finite resources.

As governments and healthcare providers continue to invest in expanding access, strengthening healthcare infrastructure and accelerating the adoption of advanced therapies, one question is becoming important, how do we ensure patients stay engaged throughout the treatment journey?

Modern healthcare has become exceptionally good at developing treatments. From biologics and precision medicines to advanced vaccines and injectable therapies, scientific innovation has transformed what is clinically possible. Yet for millions of people, especially children and patients undergoing repeated therapies, treatment is still associated with fear, anxiety, discomfort, and emotional fatigue.

These experiences are often treated as secondary concerns, but they can directly shape adherence, continuity of care and long-term health outcomes. Improving outcomes will increasingly depend not only on clinical innovation but also on how effectively treatments fit into patients’ lives.

The success of a therapy is no longer determined solely by its efficacy, but also by whether patients are willing and able to stay on treatment over time.

Healthcare must think beyond the therapy
The rapid rise of biologics, specialty medicines, and long-term injectable therapies is changing what healthcare providers need from treatment. Clinical efficacy remains essential, but it is no longer sufficient on its own. Increasingly, the value of a therapy also depends on whether it can be administered consistently, accepted by patients and sustained over the course of treatment.

India offers a clear illustration of this shift. Through initiatives such as Ayushman Bharat, implemented by the National Health Authority, healthcare access has expanded to more than 550 million beneficiaries. As more patients gain access to biologics, specialty medicines, and long-term therapies, healthcare providers are managing patients who require repeated injections over extended periods. Improving access is only part of the equation. Ensuring patients remain engaged throughout treatment is becoming just as critical.

This is not unique to India. Across Asia-Pacific, healthcare systems are responding to similar pressures. According to the MarketsandMarkets APAC Injectable Drug Delivery Market Report, the Asia-Pacific injectable drug delivery market is projected to grow at a compound annual growth rate (CAGR) of 9.8% between 2026 and 2031, driven by increasing adoption of biologics and biosimilars, expanding immunisation programmes, rising healthcare expenditure, and growing demand for patient-centric drug delivery technologies.

The growth of this market reflects a larger shift in healthcare, one where drug delivery is no longer viewed simply as the final step in treatment, but as an important contributor to adherence and real-world outcomes.

Patients expect treatments that fit into their lives. Convenience, comfort, pain management, and ease of administration are becoming important considerations alongside clinical outcomes. For healthcare providers, simplifying treatment delivery can strengthen adherence, improve clinical workflows, and ultimately lead to better outcomes.

Why drug delivery is becoming central to treatment success
One of the biggest shifts in healthcare today is that many therapies are no longer short-term interventions. Across oncology, endocrinology, fertility care, immunisation, and newer GLP-1 therapies, patients are expected to stay on treatment for months or even years. As access to advanced therapies expands across Asia, the challenge is no longer just initiating treatment, it is ensuring patients continue it.

Repeated injections can become a barrier to treatment. Global studies estimate that needle phobia affects 20 to 50% of children and nearly 20 to 30% of adults, often reducing adherence to therapies that require ongoing injections. The impact extends beyond patients — missed or delayed doses can affect outcomes, whilst frequent injections add to the burden on healthcare providers and clinical workflows.

A recent meta-analysis published in the Journal of Infection and Public Health found that Southeast Asia has the highest one-year prevalence of needlestick injuries amongst healthcare workers globally, at 58.2%. As healthcare systems across the region administer increasing volumes of injectable therapies, improving the safety and simplicity of drug delivery becomes important not only for patients but also for clinicians and hospital operations.

Treatment delivery plays a critical role in patient care. From years of daily growth hormone injections to multiple IVF injections within a single cycle, the treatment experience can influence adherence. As complex therapies become more common, pharmaceutical companies are increasingly integrating drug formulation and delivery to improve patient outcomes.

Redefining care with non-invasive drug delivery solutions 
Today, healthcare providers have access to a growing range of alternatives to conventional injections. Transdermal patches, inhalation therapies, wearable injectors, and needle-free injection systems are expanding the options available for administering medicines across different therapeutic areas. Rather than changing the medicine itself, these technologies focus on making treatment easier to deliver and easier for patients to receive.

Needle-free injection technology is one example. Using a high-pressure jet stream instead of a conventional needle, these systems deliver medication through the skin without the use of a hypodermic needle. According to the Insight Partners’ Asia Pacific Needle-Free Injection Systems Market Forecast to 2028, vaccine delivery accounted for the largest application segment in Asia-Pacific in 2022, underlining the growing role of these technologies in routine immunisation and preventive healthcare programmes across the region.

Across Asia, healthcare systems are expanding immunisation, chronic disease management, fertility treatments and biologic therapies. Delivery technologies that simplify administration and improve patient acceptance can reduce physical and psychological barriers, strengthen treatment adherence, and enable more consistent care across hospitals, outpatient clinics, and community settings.

The future of healthcare lies in integrated innovation
As healthcare systems across Asia expand access to advanced therapies, patient experience will increasingly determine whether innovation translates into better outcomes.

Beyond clinical efficacy, reducing fear, building trust and improving treatment adherence will be critical. The future of healthcare will be shaped not only by the medicines we develop, but by how confidently patients embrace and continue them.